The following table presents the changes in the carrying amount of goodwill by reportable segment and goodwill assigned to the other operating segments:


(in millions)	Cardiovascular		Neuroscience		Medical Surgical		Reportable Segments		Other Operating Segments		Total
April 26, 2024	$	7,966	$	11,644	$	19,121	$	38,731	$	2,255	$	40,986
Goodwill as a result of acquisitions	—		—		108		108		—		108
Purchase accounting adjustments	2		—		(2)		—		—		—
Currency translation and other	50		72		521		643		1		643
April 25, 2025	8,017		11,716		19,748		39,482		2,255		41,737
Goodwill as a result of acquisitions	555		—		—		555		—		555

Currency translation and other	30		61		204		295		—		295
April 24, 2026	$	8,602	$	11,777	$	19,953	$	40,332	$	2,256	$	42,587


	April 24, 2026				April 25, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,559	$	(10,596)	$	16,550	$	(9,650)
Purchased technology and patents	11,875		(8,319)		11,600		(7,514)
Trademarks and tradenames	422		(295)		421		(283)
Other	373		(126)		355		(101)
Total	$	29,229	$	(19,336)	$	28,925	$	(17,547)
Indefinite-lived:
IPR&D	$	253	$	—	$	289	$	—

The Company did not recognize any definite-lived intangible asset impairment charges during fiscal years 2026 and 2025. During fiscal year 2024, the Company recognized $295 million of definite-lived intangible asset impairment charges in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in other operating expense (income), net in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024.

There were no indefinite-lived intangible asset impairment charges during fiscal year 2026 and 2025. Indefinite-lived intangible asset impairment charges were not material for fiscal year 2024. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Intangible asset amortization expense was $1.8 billion for both fiscal years 2026 and 2025, including $121 million and $151 million, respectively, of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $1.7 billion for fiscal year 2024. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April 24, 2026, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows: